Monopar Therapeutics Inc. (NASDAQ: MNPR) had its price target raised by analysts at HC Wainwright from $6.00 to $22.00. They now have a "buy" rating on the stock.
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock [Yahoo! Finance]
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock